Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Qingdao Central Hospital

Clinical trials sponsored by Qingdao Central Hospital, explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New drug combo aims to outsmart resistant lung cancer Results expected Dec 2026 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 1 Completed 1

New drug combo aims to outsmart resistant lung cancer

Disease control Recruiting now

This phase 2 trial is testing whether adding savolitinib to osimertinib can help people with a certain type of advanced lung cancer (EGFR-mutated NSCLC) that has become resistant to osimertinib. The study enrolls 60 adults whose tumors have low levels of MET amplification. Partic…

Phase 2 • Sponsor: Qingdao Central Hospital • Aim: Disease control

Last updated Jun 27, 2026 08:08 UTC